The failure of anti-VEGF drugs has been attributed to several mechanisms, such as the recruitment of VEGF-insensitive endothelial progenitor cells (EPCs), which are mobilized from either the bone marrow or the arterial wall and support angiogenesis in several types of cancer [12, 13], including BC. This evidence concerns the gene VEGFA and cancer.